Ambrx Biopharma Inc. (AMAM) |
14.715 0.305 (2.12%)
|
06-09 13:14 |
Open: |
14.4 |
Pre. Close: |
14.41 |
High:
|
14.98 |
Low:
|
14.23 |
Volume:
|
162,451 |
Market Cap:
|
813(M) |
|
|
Technical analysis |
as of: 2023-06-09 12:43:16 PM |
Short-term rate:
|
|
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
Mid-term rate:
|
|
Target: |
Six months: 17.85 One year: 20.85 |
Support: |
Support1: 12.52 Support2: 10.81 |
Resistance: |
Resistance1: 15.28 Resistance2: 17.85 |
Pivot: |
14.11  |
Moving Average: |
MA(5): 13.81 MA(20): 13.86 
MA(100): 8.52 MA(250): 4.47  |
MACD: |
MACD(12,26): 0.7 Signal(9): 0.8  |
Stochastic oscillator: |
%K(14,3): 71.2 %D(3): 57  |
RSI: |
RSI(14): 60.4  |
52-week: |
High: 15.28 Low: 0.37 |
Average Vol(K): |
3-Month: 551 (K) 10-Days: 455 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AMAM ] has closed below upper band by 25.5%. Bollinger Bands are 33.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
14.74 - 14.8 |
14.8 - 14.87 |
Low:
|
13.2 - 13.25 |
13.25 - 13.32 |
Close:
|
14.3 - 14.39 |
14.39 - 14.51 |
|
Company Description |
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California. |
Headline News |
Tue, 06 Jun 2023 Wall Street analysts' outlook for Ambrx Biopharma Inc. (AMAM) - SETE News
Mon, 05 Jun 2023 2023-06-05 | NDAQ:AMAM | Press Release | Ambrx Biopharma Inc. - Stockhouse Publishing
Fri, 02 Jun 2023 Oppenheimer Initiates Coverage of Ambrx Biopharma Inc - ADR ... - Nasdaq
Tue, 30 May 2023 Ambrx to Present at Multiple Upcoming Investor Meetings - GlobeNewswire
Fri, 26 May 2023 Should You Add Ambrx Biopharma Inc - ADR (AMAM) Stock to Your Portfolio Friday? - InvestorsObserver
Fri, 19 May 2023 Cantor Fitzgerald Initiates Coverage of Ambrx Biopharma Inc - ADR ... - Nasdaq
|
Financial Analysis |
Price to Book Value: |
Neutral |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Neutral |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Neutral |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NYSE |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
55 (M) |
Shares Float |
9 (M) |
% Held by Insiders
|
0 (%) |
% Held by Institutions
|
94 (%) |
Shares Short
|
769 (K) |
Shares Short P.Month
|
764 (K) |
Stock Financials |
EPS
|
-1.79 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
3.3 |
Profit Margin (%)
|
0 |
Operating Margin (%)
|
-954 |
Return on Assets (ttm)
|
0 |
Return on Equity (ttm)
|
-38 |
Qtrly Rev. Growth
|
-98.5 |
Gross Profit (p.s.)
|
0.13 |
Sales Per Share
|
0.1 |
EBITDA (p.s.)
|
-0.99 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
-56 (M) |
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
PE Ratio
|
-8.27 |
PEG Ratio
|
-2.4 |
Price to Book value
|
4.46 |
Price to Sales
|
140.59 |
Price to Cash Flow
|
-14.6 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|